Pembrolizumab for melanoma- safety profile and future trends.

Martina Sanlorenzo, Igor Vujic, Adil Daud, Alain Algazi, Matthew Gubens, Sara Alcántara Luna, Kevin Lin, Pietro Quaglino, Klemens Rappersberger, Susana Ortiz-Urda, Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression JAMA Dermatology. ,vol. 151, pp. 1206- 1212 ,(2015) , 10.1001/JAMADERMATOL.2015.1916

Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F Stephen Hodi, Jacob Schachter, Anna C Pavlick, Karl D Lewis, Lee D Cranmer, Christian U Blank, Steven J O'Day, Paolo A Ascierto, April K S Salama, Kim A Margolin, Carmen Loquai, Thomas K Eigentler, Tara C Gangadhar, Matteo S Carlino, Sanjiv S Agarwala, Stergios J Moschos, Jeffrey A Sosman, Simone M Goldinger, Ronnie Shapira-Frommer, Rene Gonzalez, John M Kirkwood, Jedd D Wolchok, Alexander Eggermont, Xiaoyun Nicole Li, Wei Zhou, Adriane M Zernhelt, Joy Lis, Scot Ebbinghaus, S Peter Kang, Adil Daud, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial The Lancet Oncology. ,vol. 16, pp. 908- 918 ,(2015) , 10.1016/S1470-2045(15)00083-2

Adil Daud, Current and Emerging Perspectives on Immunotherapy for Melanoma Seminars in Oncology. ,vol. 42, pp. S3- S11 ,(2015) , 10.1053/J.SEMINONCOL.2015.10.003

Caroline Robert, Antoni Ribas, Jedd D Wolchok, F Stephen Hodi, Omid Hamid, Richard Kefford, Jeffrey S Weber, Anthony M Joshua, Wen-Jen Hwu, Tara C Gangadhar, Amita Patnaik, Roxana Dronca, Hassane Zarour, Richard W Joseph, Peter Boasberg, Bartosz Chmielowski, Christine Mateus, Michael A Postow, Kevin Gergich, Jeroen Elassaiss-Schaap, Xiaoyun Nicole Li, Robert Iannone, Scot W Ebbinghaus, S Peter Kang, Adil Daud, Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial The Lancet. ,vol. 384, pp. 1109- 1117 ,(2014) , 10.1016/S0140-6736(14)60958-2

Drew M Pardoll, Immunology beats cancer: a blueprint for successful translation. Nature Immunology. ,vol. 13, pp. 1129- 1132 ,(2012) , 10.1038/NI.2392

Michael A. Postow, Margaret K. Callahan, Jedd D. Wolchok, Immune Checkpoint Blockade in Cancer Therapy Journal of Clinical Oncology. ,vol. 33, pp. 1974- 1982 ,(2015) , 10.1200/JCO.2014.59.4358

J. D. Wolchok, A. Hoos, S. O'Day, J. S. Weber, O. Hamid, C. Lebbe, M. Maio, M. Binder, O. Bohnsack, G. Nichol, R. Humphrey, F. S. Hodi, Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria Clinical Cancer Research. ,vol. 15, pp. 7412- 7420 ,(2009) , 10.1158/1078-0432.CCR-09-1624

Douglas B. Johnson, Chengwei Peng, Jeffrey A. Sosman, Nivolumab in melanoma: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology. ,vol. 7, pp. 97- 106 ,(2015) , 10.1177/1758834014567469

Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll, Immune checkpoint blockade: a common denominator approach to cancer therapy Cancer Cell. ,vol. 27, pp. 450- 461 ,(2015) , 10.1016/J.CCELL.2015.03.001

Amita Patnaik, S. Peter Kang, Drew Rasco, Kyriakos P. Papadopoulos, Jeroen Elassaiss-Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Espino, Kevin Gergich, Liliana Delgado, Adil Daud, Jill A. Lindia, Xiaoyun Nicole Li, Robert H. Pierce, Jennifer H. Yearley, Dianna Wu, Omar Laterza, Manfred Lehnert, Robert Iannone, Anthony W. Tolcher, Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors Clinical Cancer Research. ,vol. 21, pp. 4286- 4293 ,(2015) , 10.1158/1078-0432.CCR-14-2607